The Role of Sentinel Lymph Node Biopsy and Factors Associated with Invasion in Extensive DCIS of the Breast Treated by Mastectomy: The Cinnamome Prospective Multicenter Study

Christine Tunon-de-Lara, Marie Pierre Chauvet, Marie Christine Baranzelli, Marc Baron, Jean Piquenot, Guillaume Le-Bouédec, Fréderique Penault-Llorca, Jean-Rémi Garbay, Jérôme Blanchot, Joëlle Mollard, Véronique Maisongrosse, Simone Mathoulin-Pélissier, Gaëtan MacGrogan, Christine Tunon-de-Lara, Marie Pierre Chauvet, Marie Christine Baranzelli, Marc Baron, Jean Piquenot, Guillaume Le-Bouédec, Fréderique Penault-Llorca, Jean-Rémi Garbay, Jérôme Blanchot, Joëlle Mollard, Véronique Maisongrosse, Simone Mathoulin-Pélissier, Gaëtan MacGrogan

Abstract

Background: When invasive components are discovered at mastectomy for vacuum-assisted biopsy (VAB)-diagnosed ductal carcinoma in situ (DCIS), the only option available is axillary lymph node dissection (ALND). The primary aim of this prospective multicenter trial was to determine the benefit of performing upfront sentinel lymph node (SLN) biopsy for these patients. The secondary aim was to determine DCIS factors associated with microinvasion or invasion.

Methods: The SLN procedure was performed during mastectomy, and for positive SLN an ALND was performed during the same intervention. A tissue microarray containing DCIS lesions from the mastectomy specimens was subsequently performed.

Results: From May 2008 to December 2010, 228 patients were enrolled from 14 French cancer centers, including 192 eligible patients with pure DCIS on VAB and successful SLN procedures. ALND was avoided for 51 [67 %; 95 % confidence interval (CI), 56-77 %] of all the patients who had microinvasive DCIS or DCIS associated with invasive carcinoma at mastectomy and a negative SLN. Of the 192 patients, 76 (39 %) with VAB-diagnosed DCIS were upgraded after mastectomy to micro (n = 20) or invasive disease (n = 56). The rate of positive SLN for patients with DCIS on VAB was 14 %. High nuclear grade of DCIS was associated with greater risk of microinvasion and invasion, and HER2-amplified DCIS was associated with greater risk of invasion.

Conclusions: Underestimation of invasive components is high when DCIS is diagnosed by VAB in patients undergoing mastectomy. Upfront SLN for patients with VAB-diagnosed extensive DCIS avoids unnecessary ALND for two-thirds of patients with micro or invasive disease on mastectomy.

Figures

Fig. 1
Fig. 1
Flow chart of ductal carcinoma in situ (DCIS) patients included in the study and results of the sentinel lymph node (SLN) procedure. n number of patients, ALND axillary lymph node dissection, VAB vacuum-assisted biopsy, b-DCIS vacuum-assisted biopsy-diagnosed DCIS, b-DCIS–MI vacuum-assisted biopsy-diagnosed DCIS with microinvasion, mDCIS mastectomy-diagnosed DCIS, mDCIS–MI mastectomy-diagnosed DCIS with microinvasion, mDCIS–IDC mastectomy-diagnosed DCIS with associated invasive carcinoma

References

    1. Seradour B. Breast cancer screening in France: an overview in 2009. La Revue du Praticien. 2010;60:191–199.
    1. Baxter NN, Virnig BA, Durham SB, et al. Trends in the treatment of ductal carcinoma in situ of the breast. JNCI J Natl Cancer Inst. 2004;96:443–448. doi: 10.1093/jnci/djh069.
    1. Dominguez FJ, Golshan M, Black DM, et al. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ. Ann Surg Oncol. 2008;15:268–273. doi: 10.1245/s10434-007-9610-6.
    1. Allegra CJ, Aberle DR, Ganschow P, et al. National Institutes of Health State-of-the-Science Conference Statement: diagnosis and Management of Ductal Carcinoma In Situ September 22–24, 2009. JNCI J Natl Cancer Inst. 2010;102:161–169. doi: 10.1093/jnci/djp485.
    1. Smith BL. Clinical applications of breast pathology: management of in situ breast carcinomas and sentinel node biopsy issues. Mod Pathol. 2010;23:S33–S35. doi: 10.1038/modpathol.2010.53.
    1. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98:599–609. doi: 10.1093/jnci/djj158.
    1. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595–600. doi: 10.1097/SLA.0b013e3181c0e92a.
    1. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–575. doi: 10.1001/jama.2011.90.
    1. Rodier JF, Velten M, Wilt M, et al. Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast-sparing procedures: FRANSENODE Trial. J Clin Oncol. 2007;25:3664–3669. doi: 10.1200/JCO.2006.08.4228.
    1. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–145. doi: 10.1200/JCO.2006.09.2775.
    1. de Roos MA, van der Vegt B, Peterse JL, et al. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in “pure” ductal carcinoma in situ of the breast. Histopathology. 2007;51:227–238. doi: 10.1111/j.1365-2559.2007.02754.x.
    1. Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010;102:627–637. doi: 10.1093/jnci/djq101.
    1. Cox CE, Pendas S, Cox JM, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg. 1998;227:645–51; discussion 651–3.
    1. Brennan ME, Turner RM, Ciatto S, et al. Ductal carcinoma in situ at core needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology. 2011;260:119–128. doi: 10.1148/radiol.11102368.
    1. Huo L, Sneige N, Hunt KK, et al. Predictors of invasion in patients with core needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer. 2006;107:1760–1768. doi: 10.1002/cncr.22216.
    1. Yen TWF, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005;200:516–526. doi: 10.1016/j.jamcollsurg.2004.11.012.
    1. Han JS, Molberg KH, Sarode V. Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases. Breast J. 2011;17:223–229. doi: 10.1111/j.1524-4741.2011.01069.x.
    1. Kim J, Han W, Lee JW, et al. Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision. Breast. 2012;21:641–645. doi: 10.1016/j.breast.2012.06.012.
    1. Moran CJ, Kell MR, Flanagan FL, et al. Role of sentinel lymph node biopsy in high-risk ductal carcinoma in situ patients. Am J Surg. 2007;194:172–175. doi: 10.1016/j.amjsurg.2006.11.027.
    1. Trentin C, Dominelli V, Maisonneuve P, et al. Predictors of invasive breast cancer and lymph node involvement in ductal carcinoma in situ initially diagnosed by vacuum-assisted breast biopsy: experience of 733 cases. Breast. 2012;21:635–640. doi: 10.1016/j.breast.2012.06.009.
    1. Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297–305. doi: 10.1016/S1470-2045(13)70035-4.
    1. Leidenius M, Salmenkivi K, von Smitten K, et al. Tumour-positive sentinel node findings in patients with ductal carcinoma in situ. J Surg Oncol. 2006;94:380–384. doi: 10.1002/jso.20581.
    1. Mabry H, Giuliano AE, Silverstein MJ. What is the value of axillary dissection or sentinel node biopsy in patients with ductal carcinoma in situ? Am J Surg. 2006;192:455–457. doi: 10.1016/j.amjsurg.2006.06.028.
    1. Meretoja TJ, Heikkilä PS, Salmenkivi K, et al. Outcome of patients with ductal carcinoma in situ and sentinel node biopsy. Ann Surg Oncol. 2012;19:2345–2351. doi: 10.1245/s10434-012-2287-5.
    1. Tada K, Ogiya A, Kimura K, et al. Ductal carcinoma in situ and sentinel lymph node metastasis in breast cancer. World J Surg Oncol. 2010;8:6. doi: 10.1186/1477-7819-8-6.
    1. Tunon-de-Lara C, Giard S, Buttarelli M, et al. Sentinel node procedure is warranted in ductal carcinoma in situ with high risk of occult invasive carcinoma and microinvasive carcinoma treated by mastectomy. Breast J. 2008;14:135–140. doi: 10.1111/j.1524-4741.2007.00543.x.
    1. Houvenaeghel G, Nos C, Mignotte H, et al. Micrometastases in sentinel lymph node in a multicentric study: predictive factors of nonsentinel lymph node involvement. Groupe Des Chirurgiens De La Federation Des Centres De Lutte Contre Le Cancer. J Clin Oncol. 2006;24:1814–1822. doi: 10.1200/JCO.2005.03.3225.
    1. Yi M, Krishnamurthy S, Kuerer HM, et al. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg. 2008;196:81–87. doi: 10.1016/j.amjsurg.2007.08.057.
    1. Bendifallah S, Chabbert-Buffet N, Maurin N, et al. Predictive factors for breast cancer in patients diagnosed with ductal intraepithelial neoplasia, grade 1B. Anticancer Res. 2012;32:3571–3579.
    1. Houssami N, Ambrogetti D, Marinovich ML, et al. Accuracy of a preoperative model for predicting invasive breast cancer in women with ductal carcinoma in situ on vacuum-assisted core needle biopsy. Ann Surg Oncol. 2011;18:1364–1371. doi: 10.1245/s10434-010-1438-9.
    1. Nishimura S, Takahashi K, Gomi N, et al. What is the predictor for invasion in nonpalpable breast cancer with microcalcifications? Breast Cancer. 2004;11:49–54. doi: 10.1007/BF02968002.
    1. Suh YJ, Kim MJ, Kim EK, et al. Comparison of the underestimation rate in cases with ductal carcinoma in situ at ultrasound-guided core biopsy: 14-gauge automated core needle biopsy vs 8- or 11-gauge vacuum-assisted biopsy. Br J Radiol. 2012;85:e349–e356. doi: 10.1259/bjr/30974918.
    1. Tan JC, McCready DR, Easson AM, et al. Role of sentinel lymph node biopsy in ductal carcinoma in situ treated by mastectomy. Ann Surg Oncol. 2007;14:638–645. doi: 10.1245/s10434-006-9211-9.
    1. Chin-Lenn L, Mack LA, Temple W, et al. Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy. Ann Surg Oncol. 2014;21:66–73. doi: 10.1245/s10434-013-3239-4.
    1. Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992;23:974–979. doi: 10.1016/0046-8177(92)90257-4.
    1. Perez AA, Rocha RM, Balabram D, et al. Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast. Clinics. 2013;68:674–678. doi: 10.6061/clinics/2013(05)15.
    1. Chang WC, Hsu HH, Yu JC, et al. Underestimation of invasive lesions in patients with ductal carcinoma in situ of the breast diagnosed by ultrasound-guided biopsy: a comparison between patients with and without HER2/neu overexpression. Eur J Radiol. 2014;83:935–941. doi: 10.1016/j.ejrad.2014.02.020.
    1. Shekhar MP, Kato I, Nangia-Makker P, et al. Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup. Oncotarget. 2013;4:231–241. doi: 10.18632/oncotarget.818.
    1. Siziopikou KP, Khan S. Correlation of HER2 gene amplification with expression of the apoptosis-suppressing genes bcl-2 and bcl-x-L in ductal carcinoma in situ of the breast. Appl Immunohistochem Mol Morphol. 2005;13:14–18. doi: 10.1097/00129039-200503000-00003.
    1. Lee S, Stewart S, Nagtegaal I, et al. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res. 2012;72:4574–4586. doi: 10.1158/0008-5472.CAN-12-0636.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe